Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2008 | Editorial

PET imaging with ¹¹C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective

Authors: Dmitri Soloviev, Alberto Fini, Franca Chierichetti, Adil Al-Nahhas, Domenico Rubello

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2008

Abstract

Purpose

In the present study, the potential clinical role of ¹¹C-acetate PET mainly in the differential diagnosis, in the staging and in the follow-up of prostate cancer patients is reported.

Methods

Each of the above points has been accurately investigated by studying the specific biochemical and radiobiochemical behaviour of this positron emitter compound.

Results and Conclusion

The imaging quality of ¹¹C-acetate PET and its unique mechanisms of cellular uptake, make such radiotracer a powerful tool in evaluating all the steps of the prostatic cancer.

Chierichetti F, Lessi G, Bissoli S, Fini A, Marcolin M, Saitta B, et al. Preliminary experience with 11C-Acetate and PET7CT in prostate cancer. J Nucl Med 2005;(Supplement 2):46, May.

Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan HG, et al. (11)C-Acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007;34:185-96. DOI 10.1007/s00259-006-0163-x.CrossRefPubMed

Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [11C] acetate—an agent for the study of myocardial metabolism by PET. Int J Appl Radiat Isot 1982;33:505-12.CrossRefPubMed

Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Schelbert HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res 1988;63:628-34.CrossRefPubMed

Klein LJ, Visser FC, Knaapen P, Peters JH, Teule GJJ, Visser CA, et al. Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med 2001;28:651-68. DOI 10.1007/s002590000472.CrossRefPubMed

Ho C-L, Chen S, Yeung DWC, Cheng TKC. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-9.CrossRefPubMed

Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-21.CrossRefPubMed

Dienel GA, Popp D, Drew PD, Ball K, Krisht A, Cruz NF. Preferential labelling of glial and meningeal brain tumours with [2-¹⁴C]acetate. J Nucl Med 2001;42:1243-50.PubMed

Bissoli S, Nicolato A, Foroni R, Medea S, Fini A, Marcolin M, et al. Preliminary experience with 11C-acetate in the diagnosis of suspected meningioma. Eur J Nuclear Med Mol Imaging 2006;Suppl 2:33, September.

10.

Waniewski RA, Martin DL. Preferential utilisation of acetate by astrocytes is attributable to transport. J Neurosci 1998;18:5225-33.PubMed

11.

Devlin TM editor. Textbook of biochemistry: with clinical correlations. 4th edn. USA: Wiley-Liss; 2006.

12.

Kihlberg T, Valind S, Långström B. Synthesis of [1-¹¹C], [2-¹¹C], [l-¹¹C](²H₃) and [2-¹¹C](²H₃)acetate for in vivo studies of myocardium using PET. Nucl Med Biol 1994;21:1067-72.CrossRefPubMed

13.

Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005;24:6314-22. DOI 10.1038/sj.onc.1208773.CrossRefPubMed

14.

Luong A, Hannah VC, Brown MS, Goldstein JL. Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. Biol Chem 2000;275:26458-66.CrossRef

15.

Fujino T, Kondo J, Ishikawa M, Morikawa K, Yamamoto TT. Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. J Biol Chem 2001;276:11420-6.CrossRefPubMed

16.

Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 2005;64:342-9.CrossRefPubMed

17.

Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-22.CrossRefPubMed

18.

Shreve P, Chiao P-C, Humes HD, Schwaiger M, Gross MD. Carbon-11C-acetate PET imaging in renal disease. J Nucl Med 1995;36:1595-160.PubMed

19.

Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol Regul Integr Comp Physiol 1984;247:146-53.

20.

Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16:202-8.CrossRefPubMed

21.

Schmitz JE, Kettunen MI, Hu D-E, Brindle K. ¹H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 2005;54:43-50.CrossRefPubMed

22.

Yahagi N, Shimano H, Hasegawa K, et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005;41:1316-22.CrossRefPubMed

23.

Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65.CrossRefPubMed

24.

Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res 2006;66:5287-94.CrossRefPubMed

25.

Schlichtholz B, Turyn J, Goyke E, Biernacki M, Jaskiewicz K, Sledzinski Z, et al. Enhanced citrate synthase activity in human pancreatic cancer. Pancreas 2005;30:99-104.CrossRefPubMed

26.

Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006;5:17. DOI 10.1186/1476-4598-5-17.CrossRefPubMedPubMedCentral

27.

Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005;65:6719-25.CrossRefPubMed

28.

Frohnert BI, Bernlohr DA. Regulation of fatty acid transporters in mammalian cells. Prog Lipid Res 2000;39:83-107.CrossRefPubMed

29.

Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001;15:1817-28.CrossRefPubMed

30.

Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003;1:707-15.PubMed

31.

Arunakaran J, Balasubramanian K, Srinivasan N, Aruldhas MM, Govindarajulu P. Interaction of androgens and prolactin on prostatic enzymes of the pyruvate-malate cycle involved in lipogenesis in castrated mature monkey, Macaca radiata. Cytobios 1992;70:33-40.PubMed

32.

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. ¹¹C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6.PubMed

33.

Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for ¹¹C-acetate whole-body PET. J Nucl Med 2004;45:1233-6.PubMed

Title: PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective
Authors: Dmitri Soloviev
Alberto Fini
Franca Chierichetti
Adil Al-Nahhas
Domenico Rubello
Publication date: 01-05-2008
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0662-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

PET imaging with ¹¹C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective

Abstract

Purpose

Methods

Results and Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results and Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

Erratum to PET imaging with hypoxia tracers: a must in radiation therapy

Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence

The diagnostic value of 124I-PET in patients with differentiated thyroid cancer

Evaluation of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-β-l-arabinofuranosyluracil ([18F]-l-FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-d-FMAU and [18F]FLT